Prompt Therapeutics, Inc. develops targeted cancer therapies using a proprietary technology platform that identifies and validates unique surface markers on tumor cells. Their approach focuses on creating robust, weaponized antibodies to meet significant unmet medical needs in oncology.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers lack effective targeted therapies due to the difficulty in identifying unique and accessible surface markers on tumor cells. This absence of specific targets limits the development of robust antibody-based treatments, leaving significant unmet needs in oncology.
Solution
Prompt Therapeutics is developing targeted cancer therapies by utilizing a proprietary technology platform to discover and validate unique surface markers expressed on tumor cells. This approach enables the creation of highly specific, weaponized antibodies designed to selectively target and eliminate cancer cells while sparing healthy tissue. By focusing on these unique markers, Prompt Therapeutics aims to develop more effective and less toxic cancer treatments. The company's platform identifies novel targets and generates antibodies with enhanced binding affinity and cytotoxic activity.
Target Audience
The primary target audience includes oncology researchers, pharmaceutical companies, and ultimately, cancer patients seeking more effective and targeted treatment options.
Features
- Proprietary platform for identifying and validating unique tumor-specific surface markers.
- Development of weaponized antibodies with enhanced binding affinity and cytotoxic activity.
- Focus on creating targeted therapies that selectively eliminate cancer cells.
- Antibody engineering to optimize drug delivery and minimize off-target effects.
- Preclinical validation of antibody efficacy and safety in relevant cancer models.